Industry News/Therapy

Drug Compares Favorably with Other Anti-Cancer Agents

Published in Cancer Weekly, May 8th, 1995

A study published in the April 1995 issue of the International Journal of Oncology (Vol 6:889-897 1995) on advanced non-small cell (NSC) lung cancer compared the survival of Onconase-treated patients with more than 40 published studies.

The study reported that the median survival time (MST) of 30 Phase II Onconase-treated patients was 7.7 months longer than the majority of other published single agent and combination chemotherapy clinical trials.

The MST of patients who received either supportive care or a placebo, in the studies reported, ranged from 1.9 months to 4.8 months. MST of the reported single agent chemotherapy trials range from 4.0 to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1995-05-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry